Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

With the close of 2024 and the launch of a new year, we can take a moment to look back at what was another eventful, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Ozempic, Wegovy and Mounjaro featured prominently. Known for their use in managing type 2 diabetes and aiding weight loss for ...

Investors can strategize their portfolio with Multiplo Picks, a selection of 10 stocks based on the overvalued American ...

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

In this podcast, Motley Fool analyst Asit Sharma and host Ricky Mulvey check in on the year in investing. They discuss: What most of the biggest winners in the S&P 500 had in common. Why more ...

Eli Lilly joins FDA lawsuit over tirzepatide shortage listing, as Outsourcing Facilities Association challenges removal of ...